drugset / Trial / NCT05605509
RP-6306 in Patients With Advanced Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is being done to answer the following questions: * Is the new drug, RP-6306, safe to use, and what effects does it have on cancer when given with standard treatment? * If there are specific biomarkers, do patients have an improved response to treatment compared to those without the biomarker? This study is being done to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for this type of cancer.
Timeline
- Start
- 2023-05-24
- Primary completion
- 2025-11-14
- Completion
- 2026-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Camonsertib | Small molecule | — | — |
| Comparator | Lunresertib | Small molecule | — | — |
| Comparator | FOLFIRI Protocol | Unknown | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Comparator | Irinotecan | Small molecule | — | — |
| Comparator | Leucovorin | Small molecule | — | — |
| Comparator | Trastuzumab | Monoclonal antibody | — | — |